LUN.CO : Summary for H. Lundbeck A/S - Yahoo Finance

U.S. Markets closed

H. Lundbeck A/S (LUN.CO)


Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
326.10+4.00 (+1.24%)
At close: 4:59PM CEST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close322.10
Open323.00
Bid325.50 x
Ask325.70 x
Day's Range320.70 - 327.50
52 Week Range209.40 - 327.50
Volume223,171
Avg. Volume297,764
Market Cap64.36B
Beta-0.95
PE Ratio (TTM)53.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bloomberglast month

    Lundbeck Mulls Alzheimer's Combo Therapy in Wake of Drug Failure

    H. Lundbeck A/S is looking at ways to develop combination therapies for Alzheimer’s disease as the Danish brain-disorder specialist presses forward despite recent failures in late-stage patient trials....

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of LUN.CO earnings conference call or presentation 8-Feb-17 12:00pm GMT

    Q4 2016 H Lundbeck A/S Earnings Call

  • Reuters2 months ago

    Lundbeck bets on shark antibodies for new brain drugs

    Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer's and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix. The two companies said on Thursday that Lundbeck had made an undisclosed payment to Ossianix, which has labs in Britain, following experiments in mice showing the effective transfer of potential drugs across the blood-brain barrier. Getting modern large-molecule medicines across the barrier that protects the brain is a major challenge for drug developers.